Lege Artis Medicinae

[Efficacy of maximal dose rosuvastatin therapy in significant carotis stenosis]

KONCSOS Péter

JULY 20, 2015

Lege Artis Medicinae - 2015;25(06-07)

[The main role of atherogenic dyslipidemia is known for decades. Several studies have proven the beneficial effect of statin therapy on cardiovascular morbidity and mortality. The following case report demonstrates the efficacy of high dose statin therapy regarding lipid goals and clinical signs. The presented 65 year-old female patient had a history of dyslipidemia and hypertension for over 15 years and positive cardiovascular family history. Carotid ultrasound examination showed 15-20% bilateral stenosis in 2008 whereas four years later, control ultrasound showed significant progression with 65% left-sided asymptomatic stenosis. At this time, LDL-cholesterol level was above the target; we managed to reach the recommended level with high-dose statin treatment in combination therapy with ezetimibe. Besides the lipid levels, regression of the carotid stenosis could be observed without statin-associated side effects.]

COMMENTS

0 comments

Further articles in this publication

Lege Artis Medicinae

[Permanent remission with fulvestrant therapy in hepatic metastases]

SIPŐCZ István

Lege Artis Medicinae

[Revenge with Brush and Canvas – Hardships of a Talented Female Painter]

GEREVICH József

Lege Artis Medicinae

[LAM Adherence Academy]

PÁL Csilla

Lege Artis Medicinae

[Sine morbo]

SIPKA Sándor

Lege Artis Medicinae

[Board Games in Medical Training ]

KOLLÁR János

All articles in the issue

Related contents

Lege Artis Medicinae

[Ways and tools of the organism's defence in atherosclerosis - The mysterious HDL particle]

JAKAB Lajos

[Every type of injury elicits an immediate defending, preventing response in the living organism, which involves the whole organism’s participation. In case of a single effect, the events and symptoms together can be designated as “acute phase reaction syndrome”. The pathogenic constituents' effects on the arterial wall are, however, permanent, though varying in composition and intensity. The protecting reaction serving the prevention of the continuously arising vessel wall lesion is inflammation itself. Beginning of the inflammatory phenomenon carries within itself the criteria of the acute tissue response but it takes on involuntarily chronic features as a consequence of the chronic etiology. In the arterial wall ongoing vasculitis affects all the three layers of the vessels. The HDL particle is involved in triggering and progression of vasculitis. It transports cholesterol from the tissues to the liver, defends the integrity and physiological functions of the endothelium, exerts antioxidant effects, and it has the capacity to inhibit secretion and effects of cytokines, cell migration and the thrombotic process. These are all together serving as controllers of the ongoing vasculitis in the artery wall. Composition of the HDL particle is exceptionally complex. Almost half of the identifiable - at least 48 - components could be considered as acute phase reactants, and almost as many are related to cholesterol and lipoprotein metabolism. Participation of proteinase inhibitors and complement system components and regulators is very important for its function. Some constituents have a glycosaminoglycan binding capacity. The physiological roles of some acute phase reactants are not completely identified as today. This is especially valid concerning the characteristics of the HDL particle as an entity. Nevertheless, on the basis of present study data, it is ascertainable that HDL is an acute phase reactant; it is an inherent part of the natural, innate immune system of the organism. However, it is only one single component of the large group of the anti-inflammatory mechanisms and factors.]

Lege Artis Medicinae

[“BONE” IN THE VESSELS, “FAT” IN THE BONES? - THE THEORY AND CLINICAL SIGNIFICANCE OF VASCULAR CALCIFICATION]

SPEER Gábor, LAKATOS Péter

[Pathologist have recognized arterial calcification for over a century described also by Virchow in the 19th century. Vascular calcification, an active mechanism, involves a complex, regulated process of biomineralization resembling osteogenesis. Evidence indicates that proteins controlling bone mineralization are also involved in the regulation of vascular calcification. The atherosclerotic plaque calcification can be easily detected noninvasively with radiological methods currently available and it correlates with the amount of atherosclerotic plaque. Also, it serves as a surrogate measure for atherosclerosis, allowing preclinical detection of the disease. There are several examples for the relationship between hyperlipidaemia and increased loss of bone mass. It is not surprising that the base drugs for osteoporosis also have the characteristics for lowering vascular calcification and are antiatherogenous and antilipaemic drugs. The clinical importance ot these facts is that vascular calcification is associated with higher risk of cardiovascular events. In the summary, the authors review the four histopathological types of arterial calcification and the molecules and proteins involved in these processes.]

Lege Artis Medicinae

[How many cardiovascular events can be avoided by a lipid lowering therapy based on preventive guidelines?]

MÁRK László

[The lipid lowering therapy became one of the most important elements in the cardiovascular prevention, yet it is not appropriately evaluated neither by the doctors, nor by the patients. The lipid goal attainment should to be improved according to Hungarian and international data. Using a recommendation guided lipid lowering therapy the most benefit can be expected in the patients at very high risk who alrea­dy had a cardiovascular event, where the LDL-cholesterol goal is 1.8 mmol/L. Calculating upon the data of 170000 patients of Cholesterol Treatment Trialists’ Collaboration a decrease of LDL-cholesterol level from 2.5 mmol/L to 1.8 in 100 patients in 10 years would avoid 3 myocardial infarctions, strokes or death, lowering that from 3.5 mmol/L to the goal would prevent these 3 events within 5 years. Using the traditional LDL-cholesterol lowering medication, high dose statin and ezetimibe, if the attitude of doctors and the compliance of patients would be ideal, the 1.8 mmol/L goal attainment rate would be over 80%. Unfortunately, up to now the reimbursed administration of ezetimibe in Hungary is still bound to a specialist’s recommendation, adding it to any dose of any statin an additional 20% LDL-cholesterol can be expected. The reimbursed administration of PCSK9-inhibitors is possible only based on a special request to National Health Insurance Fund. To achieve a better national cardiovascular morbidity and mortality the attitude of the doctors and the adherence of the patients to the lipid lowering therapy should be improved (it’s the goal of the present paper as well).]

LAM Extra for General Practicioners

[Similarities and differences in the renal effects of statins]

ÁBRAHÁM György

[By efficiently reducing serum cholesterol level, statins significantly decrease both cardiovascular morbidity and mortality. Decreasing LDL-cholesterol level by 1% reduces coronary mortality risk by 1%, whereas increasing HDL-cholesterol level by 1% reduces the risk by 3%. At the same time, renal failure significantly increases cardiovascular events and/or mortality compared with the population mean. It is an exciting question whether statins are able to prevent and decelerate the deterioration of kidney function deterioration, preserve GFR and decrease albuminuria. Depending on the strength of their effect, statins have different cholesterol-lowering capacity (rosuvastatin and atorvastatin are especially effective). An important question is whether these differences can be detected in the renal function as well. The results of experimental data and major clinical trials (e.g. AURORA, PLANET I-II, SHARP) are often controversial. Nevertheless, statin therapy has advantages for patients with kidney diseases, although to a lesser extent than it has in the normal population.]

Clinical Neuroscience

[IMPORTANT AIM OF STATIN THERAPY: ISCHEMIC CARDIOVASCULAR EVENT (STROKE)]

CSÁSZÁR Albert

[Statin’s treatment clearly is authorized in prevention of coronary heart disease (CHD). According to the results of many studies and meta-analyses statins can inhibit the first cerebrovascular infarct (stroke). The greater the decrease of LDL-cholesterol level the more prominent the efficacy. The effect is not so robustic compared to coronaria vessels moreover clear pleiotropic (cholesterol independent) action takes also part. It has been nowadays revealed that high dose (80 mg) atorvastatin can confine first time the development of recurrence stroke (SPARCL study), which is an important fact in the field of secondary prevention.]